Discover Our Latest News
-
Read More about Pharmacogenomics Leader Coriell Life Sciences Named Finalist in Health Value AwardsPosted on May 19, 2022Pharmacogenomics Leader Coriell Life Sciences Named Finalist in Health Value AwardsRecognized for delivering healthcare cost savings and improving health outcomes, Coriell Life Sciences (CLS) –…Read More about Pharmacogenomics Leader Coriell Life Sciences Named Finalist in Health Value Awards
-
Read More about Coriell Life Sciences Wins Second MedTech Breakthrough Award for Genomics InnovationPosted on May 5, 2022Coriell Life Sciences Wins Second MedTech Breakthrough Award for Genomics InnovationAs Coriell Life Sciences (CLS) leads the way in unlocking the power of pharmacogenomics (PGx)…Read More about Coriell Life Sciences Wins Second MedTech Breakthrough Award for Genomics Innovation
-
Read More about Coriell Life Sciences Wins Biotechnology AwardPosted on April 21, 2022Coriell Life Sciences Wins Biotechnology AwardGlobal Health & Pharma’s annual Biotechnology Awards cast a shining light on the pioneers and…Read More about Coriell Life Sciences Wins Biotechnology Award
Speaking Topics
The expert and experienced speakers at Coriell Life Sciences have spoken at a wide variety of industry and related events, focusing on population health with uncompromising scientific and medical excellence as trusted, ethical, and prudent advisors. CLS continues to go beyond genetic testing to provide clinical results that are actionable, improve lives, reduce costs, and simplify decision-making.
-
Enterprise Pharmacogenomics (PGx)
Pharmacogenomics represents a potentially powerful enhancement to current wellness and medication risk management programs. However, challenges must be addressed to successfully implement these programs especially in large populations where the members and their prescribing physicians are naïve or misinformed to the utilization of genetics for personalized prescribing. We describe the population assessment, program implementation, outcomes from our efforts, and its relevance across poly-pharmacy and working well populations.
-
Turnkey Return-to-Operations Program
The CLS Return-to-Operations (RTO) Program is a turnkey solution that goes beyond testing to include complete analytics & implementation to get businesses and schools up-and-running again & prevent further widescale disruption. Our data analytics tools & testing infrastructure combine health claims, company demographics, COVID-19 progression, individualized job hazard exposure, & business priorities to provide decision support and execution employers need today.
Available Speakers
-
Scott MegillPresident and Chief Executive OfficerRead More about Scott Megill
Scott Megill is President and Chief Executive Officer of Coriell Life Sciences (CLS). With a vision to translate decades of cutting-edge...
-
Jeffrey A. Shaman, PhD, MSChief Science OfficerRead More about Jeffrey A. Shaman, PhD, MS
Jeffrey Shaman, PhD, MS, is the Chief Science Officer at Coriell Life Sciences where he oversees the company’s research, education,...
Past Events
-
Philadelphia, PAAmerican Public Health Forum (APHA) 2019
-
Orlando, FLPharmacy Benefit Management Institute’s (PBMI) 25th Annual National Conference
-
Philadelphia, PANCTR 98th Annual Conference
-
Philadelphia, PAPrecision Medicine Leaders Summit – Pharmacogenomics
Affiliations
-
The Chamber Go to The Chamber website.
-
Clinical Pharmacogenics Implementation Consortium Go to Clinical Pharmacogenics Implementation Consortium website.
-
EHIR Go to EHIR website.
-
Public Sector Healthcare Roundtable Go to Public Sector Healthcare Roundtable website.
-
Personalized Medicine Coalition Go to Personalized Medicine Coalition website.
-
SALGBA Go to SALGBA website.
-
Pharmacogenomics Research Network Go to Pharmacogenomics Research Network website.
